STOCK TITAN
  1. Home
  2. Sec-filings
  3. GILD
  4. [Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences Chairman & CEO Daniel O'Day sold 10,000 shares of common stock in open-market trades. The sales occurred on April 28, 2026 at prices around $128.79 and $130.01 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. Following the sales, he continues to hold more than 600,000 shares of Gilead common stock directly.

Positive

  • None.

Negative

  • None.
Insider O'Day Daniel Patrick
Role Chairman & CEO
Sold 10,000 shs ($1.29M)
Type Security Shares Price Value
Sale Common Stock 6,950 $128.7877 $895K
Sale Common Stock 3,050 $130.0111 $397K
Holdings After Transaction: Common Stock — 635,617 shares (Direct, null)
Footnotes (1)
  1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Sale prices for the transactions reported range from $128.41 to $129.325. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Shares sold (total) 10,000 shares Open-market sales of common stock on April 28, 2026
First sale block 3,050 shares at $130.0111 Non-derivative open-market sale of common stock
Second sale block 6,950 shares at $128.7877 Non-derivative open-market sale of common stock
Post-sale holdings (example line) 635,617 shares Common stock directly owned after one reported sale
Price range block 1 $128.41–$129.325 Detailed sale price range provided in footnote F2
Price range block 2 $129.42–$130.47 Detailed sale price range provided in footnote F3
Rule 10b5-1 trading plan financial
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
non-derivative financial
"transaction_type": "non-derivative""
transaction code "S" regulatory
"transaction_code": "S""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Day Daniel Patrick
(Last)(First)(Middle)
333 LAKESIDE DRIVE
(Street)
FOSTER CITY CALIFORNIA 94404
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/28/2026S(1)6,950D$128.7877(2)635,617D
Common Stock04/28/2026S(1)3,050D$130.0111(3)632,567D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
2. Sale prices for the transactions reported range from $128.41 to $129.325. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Remarks:
/s/ Amy Kim by Power of Attorney for Daniel O'Day04/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did GILEAD SCIENCES (GILD) CEO Daniel O'Day report on this Form 4?

Daniel O'Day reported selling 10,000 shares of Gilead common stock in open-market transactions. These sales were split into two trades on April 28, 2026 and disclosed as routine insider activity under SEC Form 4 reporting rules.

At what prices did GILEAD SCIENCES (GILD) shares sell in Daniel O'Day’s April 28, 2026 trades?

Daniel O'Day’s reported sales occurred at average prices of about $128.79 and $130.01 per share. Footnotes indicate detailed trade prices ranged from $128.41–$130.47, with full breakdowns available to the SEC, the company, or shareholders upon request.

How many GILEAD SCIENCES (GILD) shares does Daniel O'Day hold after these sales?

After the reported sales, Daniel O'Day continues to hold over 600,000 shares of Gilead common stock directly. Filing line items show post-transaction holdings above 630,000 shares, indicating the 10,000 shares sold represent only a small portion of his position.

Were Daniel O'Day’s GILEAD SCIENCES (GILD) stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Such plans pre-schedule trades, indicating these sales were planned in advance rather than timed opportunistically.

What type of transactions did GILEAD SCIENCES (GILD) report for Daniel O'Day on this Form 4?

The filing reports two open-market sales of common stock, each coded “S” for non-derivative dispositions. No option exercises, grants, gifts, or tax-withholding events appear, and the transaction summary shows a net sale of 10,000 shares.

How significant are Daniel O'Day’s April 28, 2026 GILEAD SCIENCES (GILD) stock sales?

The filing shows a sale of 10,000 shares while O'Day retains more than 600,000 shares. This indicates the transactions are relatively small compared with his overall direct holdings, suggesting routine portfolio management rather than a major position change.